Navigation Links
Potential new drug target to fight tuberculosis identified
Date:7/30/2008

e sought to do in this research," he says.

One of the study's innovations involved the examination of M. tuberculosis as it interacted with bone marrowderived macrophages during the infective process.

"That's a huge change from standard anti-infective research, which typically deals with the pathogen simply replicating in culture," explains Dr. Vandal. "In our experiments, we wanted to see if biochemical actors would emerge in the infective process that might be inoperative in the usual in vitro setting."

The team specifically focused on changes in the pH (acidity) of the phagosome -- a structure that macrophages use to consume and destroy pathogens, including bacteria.

"As part of this process, the phagosome becomes acidic, which is thought to contribute to its ability to break down and destroy the pathogen," Dr. Ehrt explains. "However, M. tuberculosis appears to survive the acidification process, keeping its own internal pH stable."

How does the bacteria do this, despite being surrounded by the more highly acidic phagosome? To find out, the team used a kind of genetic tweaking that effectively disabled M.tuberculosis' ability to produce a key protein lying at its membrane -- a protease (enzyme) called Rv3671c.

They then watched how the organism fared without it.

"What we observed was pretty amazing -- without functioning Rv3671c, the mutant bacterium was easily destroyed in a low-pH environment, both in culture and inside the more acidic environment of the macrophage," says Dr. Vandal. "This revealed a new point of vulnerability for the bacterium."

The experiment also broke new ground because the researchers were able to accurately gauge the bacterium's internal pH with the organism lying inside a host cell.

"The ability to make those kinds of measurements will expand research into this type of host-pathogen interaction," Dr. Nathan believes.

The next step
'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers tap into a new and potentially better source of platelets for transfusion
2. TG2 identified as potential therapeutic target in chemo-resistant ovarian cancer
3. UC San Diego researchers identify potential new drug candidates to combat bird flu
4. New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers
5. The good and the bad of a potential Alzheimers target
6. Stanford study: Bioenergy potential of reviving abandoned agricultural land
7. Indiana U scientists uncover potential key to better drugs to fight toxoplasmosis parasite
8. Scientists find potential protein biomarkers for growth hormone
9. New technology enhances therapeutic potential of cord blood stem cells
10. Potential therapy discovered for hypophosphatasia, a congenital form of rickets
11. Compound has potential for new class of AIDS drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
(Date:12/17/2014)... 15, 2014  HITLAB SM announced today its completion ... its adherence to current U.S. Food and Drug Administration ... smart device and smart phone application trials utilizing the ... "HITLAB is determined to improve global healthcare access, ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Putnam Valley, NY. (June 26 , 2012) Researchers ... transplanting two varieties of stem cells into mouse cochlea ... cells and mouse embryonic stem (ES) cells demonstrate similar ... risk of tumor growth associated with transplanting iPS cells ...
... NEVERS, France, June 26, 2012 Polar ( ... assessment technology, together with LOOK , the inventor and ... of the first clipless cycling pedals to measure cycling power ... left/right balance and power output, and send the data directly ...
... discovered a new flu-fighting role for a well-known component ... cellular biology in the UGA Franklin College of Arts ... cell-signaling protein known as IL-15 to mice infected with ... times. "We gave the IL-15 intranasally and ...
Cached Biology News:Stem cell transplantation into mouse cochlea may impact future hearing loss therapies 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 2Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 3Polar And LOOK Launch The World's First Pedal-Based Power Cycling System 4UGA study reveals flu-fighting role for well-known immune component 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)... , Jan. 22, 2015   GenoSpace , a precision ... tools to enable the broad use of genomic, imaging and ... the appointment of Michelle Munson , CEO of Aspera, ... Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn cases ... Syngenta, are in the process of being consolidated in a ... In Re: Syngenta AG MIR 162 Corn Litigation, MDL No. ... Kansas. , Management of the Syngenta GMO corn multidistrict litigation ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Aug. 16 ADVENTRX Pharmaceuticals,Inc. (Amex: ... company,focused on commercializing proprietary product candidates for ... announced that the U.S. Food and,Drug Administration ... ANX-510,or CoFactor(R) injection, which is currently being ...
... Drug Application in the Fourth ... ... positive results from a 12-week, Phase 3 clinical,trial of FENTORA(R) (fentanyl buccal ... chronic non-cancer pain,conditions. The study achieved statistical significance on the primary,endpoint. Results ...
... Presentations on the Topic of Drug Repurposing and ... Indian Clinical ... Inc., an,oncology-focused, clinical-stage biopharmaceutical company, announced today,that Chief Executive Officer, ... present at the 234th American Chemical,Society National Meeting on Sunday, ...
Cached Biology Technology:ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 2ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 2Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 3Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 4Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain 5Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
...
Biology Products: